# Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-delbrueckii-subsp-bulgaricus-atcc-11842
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. delbrueckii subsp. bulgaricus ATCC 11842, L. bulgaricus ATCC 11842, Lactobacillus bulgaricus ATCC 11842, Bulgarian yogurt culture ATCC 11842, ATCC 11842, Bulgarian bacillus ATCC 11842

## Overview

Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 is a well-characterized dairy fermentation strain whose genome encodes a complete lactase (beta-galactosidase) system enabling efficient lactose hydrolysis and lactic acid production. Its primary mechanism involves converting lactose into L-lactate and formate, acidifying the gut environment and potentially modulating mucosal immune responses.

## Health Benefits

• Efficient lactose fermentation and milk acidification (genomic evidence only)
• Potential [immunomodulatory](/ingredients/condition/immune-support) effects (general L. delbrueckii research, no ATCC 11842-specific trials)
• Production of beneficial metabolites including lactate and formate (laboratory characterization)
• Stress tolerance mechanisms that may support gut survival (genomic analysis)
• Lysine biosynthesis capability contributing to nutritional value (genome sequencing data)

## Mechanism of Action

ATCC 11842 expresses a chromosomally encoded beta-galactosidase (lacZ) that cleaves lactose into glucose and galactose, reducing luminal lactose load and supporting [digestion](/ingredients/condition/gut-health) in lactase-deficient individuals. Fermentation yields L-lactic acid and formate via the pyruvate-formate lyase pathway, lowering intestinal pH and creating a bacteriostatic environment against pathogenic species. Preliminary in vitro evidence suggests cell wall components such as exopolysaccharides and peptidoglycan fragments may interact with Toll-like receptor 2 (TLR2) and TLR4 on intestinal epithelial and dendritic cells, potentially skewing [cytokine](/ingredients/condition/inflammation) profiles toward regulatory [T-cell](/ingredients/condition/immune-support) phenotypes, though this has not been confirmed in human trials for this specific strain.

## Clinical Summary

No randomized controlled trials have been published specifically investigating ATCC 11842 as an isolated supplement in human subjects, making direct clinical evidence unavailable for this strain. Broader research on L. delbrueckii subsp. bulgaricus strains in fermented dairy products suggests modest improvement in lactose [digestion](/ingredients/condition/gut-health) symptoms, with several small trials (n = 10–40) showing reduced breath hydrogen and bloating scores compared to unfermented milk controls. [Immunomodulatory](/ingredients/condition/immune-support) effects attributed to the L. delbrueckii subspecies are largely derived from in vitro [cytokine](/ingredients/condition/inflammation) assays and rodent models, and extrapolation to ATCC 11842 specifically is speculative. Current evidence is therefore classified as preliminary to moderate for lactose tolerance support and insufficient for any immune or therapeutic claims.

## Nutritional Profile

As a freeze-dried or lyophilized [probiotic](/ingredients/condition/gut-health) bacterial strain, L. delbrueckii subsp. bulgaricus ATCC 11842 contributes minimal direct macronutrients at typical dosing (10^8–10^10 CFU). Biochemically characterized components include: cell wall peptidoglycan and exopolysaccharides (EPS), which act as fermentable substrates and immune-signaling compounds; D-lactate and L-lactate as primary fermentation end-products (primary metabolic output in dairy matrices); formate produced via pyruvate formate-lyase activity (genomically confirmed); and folate precursors, though biosynthetic capacity is limited compared to other lactobacilli. Lysine biosynthesis genes are present in the ATCC 11842 genome (confirmed via complete genome sequencing, GenBank accession CR954253), contributing trace free amino acids to fermented substrates. The strain produces acetaldehyde (~1–10 ppm range in yogurt fermentation), the primary flavor compound of yogurt, which also has weak [antimicrobial](/ingredients/condition/immune-support) properties. Cell membrane contains fatty acids including oleic and vaccenic acid derivatives. Bioavailability of metabolites is substrate-dependent; in dairy matrices, lactate and acetaldehyde are directly bioavailable, while EPS interactions with gut epithelium occur at the mucosal surface. No significant direct vitamin or mineral contribution is documented for this specific strain at physiological doses.

## Dosage & Preparation

No clinically studied dosage ranges are available for ATCC 11842. The strain is primarily used in food fermentation at optimal growth temperature of 42°C for yogurt production rather than as a therapeutic supplement. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L. delbrueckii subsp. bulgaricus ATCC 11842 has a long history of safe use in yogurt fermentation and is generally recognized as safe (GRAS) by the FDA for food applications, with no documented serious adverse events in healthy populations. Individuals with severe immune compromise (e.g., post-transplant patients, advanced HIV) should exercise caution with all live bacterial strains due to rare reports of bacteremia associated with [probiotic](/ingredients/condition/gut-health) use as a class. No specific drug interactions have been identified for ATCC 11842; however, concurrent antibiotic use may reduce viability and efficacy, and timing supplementation at least two hours apart from antibiotics is a standard precaution. Pregnancy and lactation safety data specific to this strain are absent, though fermented dairy products containing this bacterium have a long history of consumption without documented harm in pregnant women.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically for ATCC 11842 were identified in the available research. Evidence is limited to genomic and physiological characterization studies focusing on its use as a yogurt starter culture, with strain-specific research examining sugar transport mutants and fermentation properties rather than clinical health outcomes.

## Historical & Cultural Context

ATCC 11842 was isolated from Bulgarian yogurt in 1919, representing centuries-old Bulgarian fermentation traditions. The strain has been valued for its role in yogurt production, contributing to milk preservation and acidification, though no evidence exists for use in formalized traditional medicine systems beyond dairy fermentation.

## Synergistic Combinations

ATCC 11842 pairs most powerfully with Streptococcus thermophilus (classic yogurt co-culture), where proto-cooperation drives mutual growth stimulation: S. thermophilus produces formate and CO2 that accelerate L. bulgaricus growth, while L. bulgaricus proteolytic activity releases peptides (including valine and histidine) that feed S. thermophilus, collectively accelerating acidification and EPS production beyond either strain alone. Lactulose or inulin-type fructooligosaccharides (FOS, 3–10g dose range) act as synbiotic partners by selectively stimulating colonic fermentation environments that favor lactate-producing bacteria, while also supporting the mucosal IgA response that complements the strain's documented [immunomodulatory](/ingredients/condition/immune-support) EPS signaling via TLR2/TLR4 pathways. A third synergy exists with Lactobacillus acidophilus NCFM, whose complementary L-lactate production pathway and superior acid-bile tolerance compensates for ATCC 11842's relatively limited lower-GI survival, creating additive colonization coverage across both small intestine and colon compartments; the combined lactate output also competitively inhibits pathobionts more effectively than either strain independently.

## Frequently Asked Questions

### What makes Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 different from other probiotic strains?

ATCC 11842 is the type strain for L. delbrueckii subsp. bulgaricus and serves as a genomic reference strain, with its full genome sequenced and annotated to characterize genes for lactose metabolism, stress response, and exopolysaccharide production. Unlike broad-spectrum probiotic strains such as Lactobacillus rhamnosus GG, ATCC 11842 is primarily studied as a dairy fermentation organism rather than a therapeutic supplement, meaning clinical human trial data for isolated supplementation are essentially nonexistent for this specific strain.

### Can Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 help with lactose intolerance?

ATCC 11842 produces beta-galactosidase, which can hydrolyze lactose both within fermented dairy products and, to a limited extent, within the gut after ingestion of live bacteria. Studies on L. bulgaricus-containing yogurts generally show reduced breath hydrogen production and lower symptom scores (bloating, cramping) compared to unfermented milk, though these studies use mixed starter cultures and do not isolate this strain's contribution. Consuming it as part of live-culture yogurt is the most evidence-supported delivery method for lactose tolerance benefits.

### Is Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 available as a standalone supplement?

ATCC 11842 is not widely marketed as a standalone probiotic supplement; it is primarily used as a commercial yogurt starter culture in combination with Streptococcus thermophilus. Some multi-strain probiotic formulations may include L. delbrueckii subsp. bulgaricus without specifying the ATCC 11842 designation, so consumers looking for this exact strain should verify strain identification on product labels, as probiotic strain identity significantly influences biological activity.

### What metabolites does Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 produce and why do they matter?

This strain produces L-lactic acid as its primary fermentation end product, along with formate generated through the pyruvate-formate lyase enzyme system during anaerobic growth. L-lactate lowers intestinal pH, inhibiting growth of pH-sensitive pathogens such as certain Enterobacteriaceae, while formate has been identified as a carbon source for cross-feeding beneficial colonic bacteria like Bifidobacterium species. Exopolysaccharides secreted during growth may also contribute to gut mucus layer interactions, though functional significance in humans remains under investigation.

### Does Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 survive passage through the human gut?

Genomic and in vitro studies show ATCC 11842 carries genes for bile salt and acid stress responses, including chaperone proteins (groEL, dnaK) and an F0F1-ATPase proton pump that helps maintain intracellular pH under acidic conditions. Despite these adaptations, L. delbrueckii subsp. bulgaricus strains are generally considered transient colonizers rather than permanent residents of the human gut, with recovery in feces declining rapidly after supplementation ceases. Its beneficial effects are therefore thought to occur primarily during transit rather than through stable intestinal colonization.

### Is Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 safe for children and elderly individuals?

Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 is generally recognized as safe (GRAS) and is commonly found in fermented dairy products consumed across all age groups. However, immunocompromised elderly individuals or children with severe underlying conditions should consult a healthcare provider before taking high-dose probiotic supplements. Clinical safety data specific to this strain in pediatric and geriatric populations remains limited, so dose appropriateness should be individualized.

### Does Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 interact with antibiotics or other medications?

Antibiotics, particularly broad-spectrum agents, can reduce the viability of Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 and diminish its effectiveness. Best practice is to separate probiotic supplementation from antibiotic doses by at least 2–3 hours. No specific contraindications with non-antibiotic medications are documented, though individuals taking immunosuppressant drugs should seek medical guidance before supplementing.

### What food sources naturally contain Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842?

This strain is a primary starter culture in traditional yogurt production, making yogurt containing live and active cultures the most accessible natural food source. Bulgarian yogurt and some European fermented dairy products are particularly rich in this subspecies. Consuming fermented dairy products regularly may provide adequate exposure for most individuals, though therapeutic supplement doses typically exceed what food alone delivers.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*